Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Ruggiero

Showing results (41-50 of 134) with videos related to

Pageof 14
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|June 16, 2023
Comment on: 'Clinical characteristics of patients with pityriasis rubra pilaris following SARS-CoV-2 vaccination' by GambichlerLuca Potestio, Fabrizio Martora, Alessia Villani, et al.
The Australasian Journal of Dermatology|January 23, 2023
Cutaneous adverse reaction following COVID-19 vaccination: Report from a southern Italian referral centre. Comment on "cutaneous adverse reactions following the Pfizer/BioNTech COVID-19 vaccine" by Luo et alFabrizio Martora, Alessia Villani, Claudio Marasca, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 7, 2023
Reply to "Dalbavancin for the treatment of severe hidradenitis suppurativa"Fabrizio Martora, Angelo Ruggiero, Luca Potestio, et al.
The Journal of Dermatological Treatment|May 19, 2020
Safety of dupilumab in atopic patients during COVID-19 outbreakMaddalena Napolitano, Cataldo Patruno, Angelo Ruggiero, et al.
International Journal of Dermatology|May 3, 2020
Secukinumab: a potential safe option in psoriasis patients affected by multiple sclerosis?Matteo Megna, Claudio Marasca, Angelo Ruggiero, et al.
Journal of the American Academy of Dermatology|December 10, 2020
Dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor sonidegib to manage adverse effects: A retrospective case seriesAlessia Villani, Claudia Costa, Gabriella Fabbrocini, et al.
The Journal of Dermatological Treatment|January 31, 2022
Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life studyMatteo Megna, Luca Potestio, Angelo Ruggiero, et al.
Psoriasis (Auckland, N.Z.)|May 11, 2023
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current LiteratureLuca Potestio, Angelo Ruggiero, Gabriella Fabbrocini, et al.
Dermatology (Basel, Switzerland)|July 14, 2020
Skin Needling in Combination with Antimicrobial Peptides for the Treatment of Keloids: A Novel Perspective Proposal and Approach for Skin ScarsClaudio Marasca, Angelo Ruggiero, Dario Marasca, et al.
The Journal of Dermatological Treatment|July 25, 2020
Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experienceMatteo Megna, Gabriella Fabbrocini, Eleonora Cinelli, et al.
Pageof 14

Showing results (41-50 of 134) with videos related to

Sort By:
Pageof 14
Journal of the European Academy of Dermatology and Venereology : JEADV|June 16, 2023
Comment on: 'Clinical characteristics of patients with pityriasis rubra pilaris following SARS-CoV-2 vaccination' by GambichlerLuca Potestio, Fabrizio Martora, Alessia Villani, et al.
The Australasian Journal of Dermatology|January 23, 2023
Cutaneous adverse reaction following COVID-19 vaccination: Report from a southern Italian referral centre. Comment on "cutaneous adverse reactions following the Pfizer/BioNTech COVID-19 vaccine" by Luo et alFabrizio Martora, Alessia Villani, Claudio Marasca, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 7, 2023
Reply to "Dalbavancin for the treatment of severe hidradenitis suppurativa"Fabrizio Martora, Angelo Ruggiero, Luca Potestio, et al.
The Journal of Dermatological Treatment|May 19, 2020
Safety of dupilumab in atopic patients during COVID-19 outbreakMaddalena Napolitano, Cataldo Patruno, Angelo Ruggiero, et al.
International Journal of Dermatology|May 3, 2020
Secukinumab: a potential safe option in psoriasis patients affected by multiple sclerosis?Matteo Megna, Claudio Marasca, Angelo Ruggiero, et al.
Journal of the American Academy of Dermatology|December 10, 2020
Dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor sonidegib to manage adverse effects: A retrospective case seriesAlessia Villani, Claudia Costa, Gabriella Fabbrocini, et al.
The Journal of Dermatological Treatment|January 31, 2022
Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life studyMatteo Megna, Luca Potestio, Angelo Ruggiero, et al.
Psoriasis (Auckland, N.Z.)|May 11, 2023
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current LiteratureLuca Potestio, Angelo Ruggiero, Gabriella Fabbrocini, et al.
Dermatology (Basel, Switzerland)|July 14, 2020
Skin Needling in Combination with Antimicrobial Peptides for the Treatment of Keloids: A Novel Perspective Proposal and Approach for Skin ScarsClaudio Marasca, Angelo Ruggiero, Dario Marasca, et al.
The Journal of Dermatological Treatment|July 25, 2020
Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experienceMatteo Megna, Gabriella Fabbrocini, Eleonora Cinelli, et al.
Pageof 14